Bristol Myers Squibb (BMS; NYSE: BMY) has presented results from Phase I and Phase I/II trials for combination therapies with golcadomide, a potential first-in-class drug from the company’s CELMoD line of protein degraders, in the treatment of non-Hodgkin lymphomas. The Phase I study indicated that previously untreated patients with aggressive B-cell lymphoma who completed a regimen of golcadomide plus rituximab and chemotherapy achieved an overall response rate (ORR) of 84.5% and a minimal residual disease negativity rate of 93%. Additionally, target protein Ikaros levels decreased by over 80%, which is anticipated to enhance the antitumor activity of T and NK cells.
In the dose expansion segment of the Phase I/II trial, which focused on heavily pre-treated patients with relapsed/refractory non-Hodgkin lymphoma, golcadomide plus rituximab resulted in an ORR of 42%, a complete response rate (CRR) of 19%, and a median duration of response of 7.5 months.
Treatment-emergent adverse events (TEAEs) in both studies were primarily hematologic, with one death during the second trial attributed to the candidate therapy. Despite this, BMS intends to continue evaluating golcadomide in B-cell lymphomas.- Flcube.com
